

Raghav Sundar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2118563/publications.pdf>

Version: 2024-02-01

123
papers

2,879
citations

236833

25
h-index

206029

48
g-index

131
all docs

131
docs citations

131
times ranked

4042
citing authors

#	ARTICLE	IF	CITATIONS
1	UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1475-1484.	2.4	26
2	Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. <i>Gut</i> , 2023, 72, 226-241.	6.1	6
3	Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. <i>Gut</i> , 2022, 71, 676-685.	6.1	21
4	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. <i>Gut</i> , 2022, 71, 1277-1288.	6.1	23
5	Small bowel adenocarcinoma in Crohn's disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes. <i>International Journal of Colorectal Disease</i> , 2022, 37, 239-250.	1.0	7
6	Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer. <i>Cancer Discovery</i> , 2022, 12, 670-691.	7.7	165
7	Association of obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality: a systematic review and meta-analysis. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 1427-1440.	1.4	18
8	Distinct spatio-temporal and spectral brain patterns for different thermal stimuli perception. <i>Scientific Reports</i> , 2022, 12, 919.	1.6	4
9	Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 731223.	1.3	4
10	Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 392-402.	0.8	87
11	Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. <i>BMJ</i> , The, 2022, 376, e068632.	3.0	253
12	Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2248-2256.	3.2	3
13	KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves. <i>BMC Medical Research Methodology</i> , 2022, 22, 93.	1.4	9
14	A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210875.	1.4	4
15	Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. <i>Cancer Research</i> , 2022, 82, 2538-2551.	0.4	7
16	Pan-cancer pervasive upregulation of 3' UTR splicing drives tumorigenesis. <i>Nature Cell Biology</i> , 2022, 24, 928-939.	4.6	18
17	Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis. <i>Journal of Clinical Oncology</i> , 2022, 40, 2830.	0.8	23
18	Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. <i>Gastric Cancer</i> , 2022, 25, 741-750.	2.7	42

#	ARTICLE	IF	CITATIONS
19	Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2022, 172, 65-75.	1.3	24
20	Resistance to systemic immune checkpoint inhibition in the peritoneal niche. , 2022, 10, e004749.		6
21	Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial. <i>Liver Cancer</i> , 2022, 11, 451-459.	4.2	3
22	Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. <i>Gut</i> , 2021, 70, 1823-1832.	6.1	38
23	Safety, pharmacokinetics and tissue penetration of PIPAC paclitaxel in a swine model. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1124-1131.	0.5	8
24	PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 1875-1881.	3.2	40
25	The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 247-247.	0.8	0
26	Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.. <i>Journal of Clinical Oncology</i> , 2021, 39, 165-165.	0.8	2
27	Wearable Physiological Stress Monitoring Systemâ€”A Proof-of-Concept Study. , 2021, , 623-633.		1
28	â€œ3Gâ€•Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. <i>Cancer Research</i> , 2021, 81, 2788-2798.	0.4	9
29	Lowâ€•dose pembrolizumab in the treatment of advanced nonâ€•small cell lung cancer. <i>International Journal of Cancer</i> , 2021, 149, 169-176.	2.3	24
30	Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence System (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial. <i>Frontiers in Digital Health</i> , 2021, 3, 635524.	1.5	18
31	Abstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial. , 2021, ,		0
32	Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer. <i>Genome Medicine</i> , 2021, 13, 158.	3.6	7
33	Cryotherapy for Prevention of Taxane-Induced Peripheral Neuropathy: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 781812.	1.3	6
34	A Systematic Review and Meta-Analysis of the Effectiveness of Neuroprotectants for Paclitaxel-Induced Peripheral Neuropathy. <i>Frontiers in Oncology</i> , 2021, 11, 763229.	1.3	9
35	Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. <i>Journal of Biological Chemistry</i> , 2020, 295, 1143-1152.	1.6	19
36	Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2020, 28, 3691-3699.	1.0	17

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 847-857.	0.6	49
38	A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. <i>BMC Cancer</i> , 2020, 20, 1118.	1.1	5
39	Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group's Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 246.	1.0	27
40	Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5320-5328.	3.2	14
41	Limb Hypothermia for the Prevention of Chemotherapy-Induced Peripheral Neuropathy – Modality for Optimal Cooling. , 2020, 2020, 5061-5064.		3
42	Profiling of gastric cancer cell-surface markers to achieve tumour's normal discrimination. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000452.	1.1	6
43	A Limb Hypothermia Wearable for Chemotherapy-Induced Peripheral Neuropathy: A Mixed-Methods Approach in Medical Product Development. <i>Frontiers in Digital Health</i> , 2020, 2, 573234.	1.5	2
44	Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. <i>BMC Cancer</i> , 2020, 20, 1210.	1.1	9
45	Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 4494-4502.	3.2	38
46	Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 763.	1.3	32
47	Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1501-1512.	1.0	62
48	Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. <i>Journal of Biological Chemistry</i> , 2020, 295, 1143-1152.	1.6	17
49	Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19385-e19385.	0.8	1
50	Safety and tolerability of oxaliplatin based pressurized intraperitoneal aerosol chemotherapy (PIPAC) for patients with peritoneal carcinomatosis: A phase I dose-finding study in Asian patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 360-360.	0.8	2
51	Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1019-1019.	0.8	25
52	The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16623-e16623.	0.8	0
53	Concomitant limb cryocompression and scalp cooling to reduce paclitaxel-induced neuropathy and alopecia.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24157-e24157.	0.8	1
54	Molecular profiling of metastatic breast cancer (MBC) and target-based therapeutic matching in an Asian tertiary phase I oncology unit.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3561-3561.	0.8	1

#	ARTICLE	IF	CITATIONS
55	The chemo-brain effect in colorectal cancer patients.. Journal of Clinical Oncology, 2020, 38, e24095-e24095.	0.8	0
56	Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead. Journal of Clinical Oncology, 2019, 37, 3066-3068.	0.8	9
57	First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics, 2019, 18, 531-540.	1.9	49
58	Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane and platinum-based chemotherapy. Brain and Behavior, 2019, 9, e01312.	1.0	70
59	Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Supportive Care in Cancer, 2019, 27, 4753-4762.	1.0	25
60	Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer, 2019, 19, 132.	1.1	126
61	DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal of Cancer, 2019, 123, 48-57.	1.3	5
62	Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time. BMC Cancer, 2019, 19, 1151.	1.1	23
63	Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Annals of Oncology, 2019, 30, 424-430.	0.6	44
64	A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).. Journal of Clinical Oncology, 2019, 37, 1045-1045.	0.8	2
65	Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein-Barr virus positive gastric cancer.. Journal of Clinical Oncology, 2019, 37, e15509-e15509.	0.8	1
66	DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.. Journal of Clinical Oncology, 2019, 37, 43-43.	0.8	1
67	Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials.. Journal of Clinical Oncology, 2019, 37, e18175-e18175.	0.8	0
68	Resisting resistance to cancer immunotherapy. Thoracic Cancer, 2018, 9, 507-508.	0.8	8
69	The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials. European Journal of Cancer, 2018, 95, 20-29.	1.3	14
70	Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards?. Cancer Discovery, 2018, 8, 14-16.	7.7	10
71	Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clinical Oncology, 2018, 30, 185-191.	0.6	3
72	Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. British Journal of Cancer, 2018, 118, 312-324.	2.9	184

#	ARTICLE	IF	CITATIONS
73	P1.01-38 A Phase II With a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S474-S475.	0.5	0
74	A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. <i>European Journal of Cancer</i> , 2018, 104, 32-38.	1.3	15
75	Biomarkers for Homologous Recombination Deficiency in Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 704-713.	3.0	223
76	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 280-284.	1.0	33
77	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3C" Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5272-5281.	3.2	20
78	Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. <i>European Journal of Cancer</i> , 2018, 101, 55-61.	1.3	6
79	A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. <i>BMC Cancer</i> , 2018, 18, 332.	1.1	32
80	Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1918-1925.	0.6	26
81	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. <i>Gastric Cancer</i> , 2018, 21, 1064-1070.	2.7	25
82	Cryocompression for enhanced limb hypothermia in preventing paclitaxel-induced peripheral neuropathy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10095-10095.	0.8	2
83	Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases.. <i>Journal of Clinical Oncology</i> , 2018, 36, 125-125.	0.8	0
84	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16024-e16024.	0.8	0
85	Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2588-2588.	0.8	1
86	Targeting ATR in cancer medicine. <i>Current Problems in Cancer</i> , 2017, 41, 302-315.	1.0	43
87	Targeting <i>BRAF</i> -Mutant Colorectal Cancer: Progress in Combination Strategies. <i>Cancer Discovery</i> , 2017, 7, 558-560.	7.7	25
88	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2017, 77, 813-827.	4.9	42
89	Emerging biomarkers for PD-1 pathway cancer therapy. <i>Biomarkers in Medicine</i> , 2017, 11, 53-67.	0.6	11
90	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 25-40.	4.0	87

#	ARTICLE	IF	CITATIONS
91	Combining Molecularly Targeted Agents: Is More Always Better?. <i>Clinical Cancer Research</i> , 2017, 23, 1123-1125.	3.2	6
92	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 39.	1.2	18
93	Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy. <i>Annals of Oncology</i> , 2017, 28, v422.	0.6	0
94	Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital. <i>Annals of Oncology</i> , 2017, 28, v132-v133.	0.6	0
95	Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10536-10536.	0.8	1
96	Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1056-1056.	0.8	1
97	First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2546-2546.	0.8	4
98	Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8556-8556.	0.8	10
99	TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2571-2571.	0.8	0
100	Dose-exposure-response relationship between AZD6738 and peripheral monocytes.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14063-e14063.	0.8	6
101	Adherence to novel oral anticancer therapies in the phase I setting: The Royal Marsden experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2542-2542.	0.8	4
102	Genomic predictors of neoadjuvant chemotherapy (NACT) response in breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e12122-e12122.	0.8	1
103	Whole exome sequencing (WES) of multiple spatially distinct biopsies from single metastatic lesions to evaluate tumour heterogeneity and identify actionable truncal mutations (ATMs) in patients (pts) with advanced solid malignancies using a radiologically-guided single-pass percutaneous technique.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2550-2550.	0.8	0
104	Abstract 3807: ATM protein loss and clinical outcomes with platinum chemotherapy in patients with advanced solid tumors. , 2017, , .		0
105	Abstract 3081: Precision medicine for patients with advanced small cell lung cancer treated with novel therapeutic agents in a phase I clinical trials unit. , 2017, , .		0
106	Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. <i>Current Cancer Therapy Reviews</i> , 2016, 12, 23-36.	0.2	0
107	Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy. <i>PLoS ONE</i> , 2016, 11, e0164319.	1.1	9
108	Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit. <i>Annals of Oncology</i> , 2016, 27, vi130.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Hypothermia for preventing chemotherapy-induced neuropathy – a pilot study on safety and tolerability in healthy controls. <i>Acta Oncologica</i> , 2016, 55, 430-436.	0.8	17
110	RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity. <i>Annals of Oncology</i> , 2016, 27, vi122.	0.6	2
111	Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study. <i>Frontiers in Oncology</i> , 2016, 6, 274.	1.3	32
112	Randomised study of 2 low doses of sunitinib to modulate tumor microvasculature prior to chemotherapy in nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6034-6034.	0.8	1
113	A phase II randomized study of docetaxel +/- low-dose, short course sunitinib in advanced solid tumours.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14124-e14124.	0.8	1
114	Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. <i>Oncotarget</i> , 2016, 7, 64089-64099.	0.8	16
115	The role of limb hypothermia in preventing paclitaxel-induced peripheral neuropathy.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21696-e21696.	0.8	1
116	Zinner syndrome: an uncommon cause of painful ejaculation. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014207618-bcr2014207618.	0.2	26
117	Nivolumab in NSCLC: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 85-96.	1.4	196
118	Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2542-2542.	0.8	2
119	The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 770-770.	0.8	3
120	Immunotherapy in the treatment of non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 101-109.	0.9	106
121	Phase II study of neoadjuvant weekly paclitaxel and carboplatin with lapatinib in HER2+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 619-619.	0.8	2
122	Effect of low-dose, short-course sunitinib (Su) on tumor vasculature and tumor blood flow for enhancement of chemotherapy efficacy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1060-1060.	0.8	0
123	Selective Internal Radiation Therapy With Yttrium-90 Resin Microspheres Followed by Gemcitabine Plus Cisplatin for Unresectable Intra-Hepatic Cholangiocarcinoma: A Phase II Single-Arm Multicenter Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0